Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

BACKGROUND: Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac safety of pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, S M, Ewer, M S, Viale, G, Delaloge, S, Ferrero, J -M, Verrill, M, Colomer, R, Vieira, C, Werner, T L, Douthwaite, H, Bradley, D, Waldron-Lynch, M, Kiermaier, A, Eng-Wong, J, Dang, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888999/
https://www.ncbi.nlm.nih.gov/pubmed/29253081
http://dx.doi.org/10.1093/annonc/mdx773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888999/
https://www.ncbi.nlm.nih.gov/pubmed/29253081
http://dx.doi.org/10.1093/annonc/mdx773

Ejemplares similares